TriSalus Life Sciences Names Liselotte Hyveled to Board

TriSalus Life Sciences Inc., an established oncology firm specializing in innovative therapeutic delivery systems, has announced the addition of Liselotte Hyveled to its Board of Directors. This strategic appointment aims to leverage Hyveled's extensive experience in pharmaceutical innovation and research and development to advance the company's mission of transforming treatments for liver and pancreatic cancers.

Hyveled brings over 20 years of experience in driving scientific advancements and enhancing pharmaceutical pipelines. Currently, she serves as the Chief Patient Officer at Novo Nordisk, where she integrates patient needs and perspectives into the company's decision-making and operational processes. Her career at Novo Nordisk has been marked by her commitment to research excellence, breakthrough innovations, and patient-focused solutions. Additionally, she has led several social responsibility initiatives focused on neurodiversity, disabilities, and generational intelligence.

"We are excited to welcome Liselotte to our Board of Directors as we move forward with the commercialization of the TriNav Infusion System and advance our therapeutic pipeline through significant milestones in 2024 and beyond," stated Mats Wahlstrom, Chairman of the Board at TriSalus. Wahlstrom emphasized that Hyveled's extensive experience and strategic insights will be crucial in shaping TriSalus' long-term vision of pioneering innovative treatments for liver and pancreatic cancers. "We anticipate that Liselotte's contributions will be instrumental to our ongoing success," he added.

Mary Szela, President and CEO of TriSalus, highlighted that Hyveled's background in fostering patient-centric innovations and strategic planning will be invaluable as the company continues to grow. "Her guidance will be pivotal in expanding and scaling our operations while accelerating the development of our technology and therapeutic pipelines," Szela noted.

Hyveled expressed her enthusiasm about joining the TriSalus team, acknowledging the company's groundbreaking platform aimed at addressing the complexities of liver and pancreatic cancers. "I am honored to collaborate with the TriSalus board and leadership team to build upon the company's achievements and realize its vision of transforming patient outcomes," she remarked.

TriSalus Life Sciences is focused on oncology and aims to improve drug delivery to liver and pancreatic tumors. The company’s platform features devices that utilize proprietary drug delivery technology alongside a clinical-stage investigational immunotherapy. The TriNav Infusion System, approved by the FDA, is designed for hepatic arterial infusion of liver tumors, while another system targets pancreatic tumors using a novel approach known as Pressure-Enabled Drug Delivery (PEDD). This method modulates pressure and flow to enhance therapeutic delivery to tumors, minimizing exposure to normal tissues and potentially improving patient outcomes.

Additionally, TriSalus is developing nelitolimod, an investigational immunotherapeutic candidate. This drug is designed to enhance patient outcomes by addressing the immunosuppressive environment created by many tumors, which often renders current immunotherapies ineffective. Data from clinical trials suggest that nelitolimod, when delivered using PEDD, may have positive immune effects both within the liver and throughout the body.

Partnering with leading cancer centers nationwide, TriSalus leverages deep immuno-oncology expertise and innovative technology development to advance treatments that improve patient outcomes.